Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Linardou, H; Dahabreh, IJ; Bafaloukos, D; Kosmidis, P; Murray, S

dc.contributor.author	Linardou, H	en
dc.contributor.author	Dahabreh, IJ	en
dc.contributor.author	Bafaloukos, D	en
dc.contributor.author	Kosmidis, P	en
dc.contributor.author	Murray, S	en
dc.date.accessioned	2014-03-01T11:46:24Z
dc.date.available	2014-03-01T11:46:24Z
dc.date.issued	2009	en
dc.identifier.issn	1759-4774	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/37871
dc.subject.other	CELL-LUNG-CANCER	en
dc.subject.other	GROWTH-FACTOR-RECEPTOR	en
dc.subject.other	PHASE-III TRIAL	en
dc.subject.other	GENE COPY NUMBER	en
dc.subject.other	METASTATIC COLORECTAL-CANCER	en
dc.subject.other	PREVIOUSLY TREATED PATIENTS	en
dc.subject.other	GEFITINIB TREATMENT	en
dc.subject.other	ACQUIRED-RESISTANCE	en
dc.subject.other	MONOCLONAL-ANTIBODIES	en
dc.subject.other	PROGNOSTIC INDICATORS	en
dc.title	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC	en
heal.type	other	en
heal.language	English	en
heal.publicationDate	2009	en
heal.abstract	Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced rapid, durable, complete or partial responses. These data were the basis for attempts to identify specific subgroups of patients who would further benefit from these agents. The discovery of somatic mutations in EGFR that correlated with sensitivity to TKIs identified a plausible explanation for these observations. Clinical and pathological factors such as female sex, never having smoked, Asian origin and adenocarcinoma histology correlate with the presence of EGFR mutations and objective responses to TKIs in patients with NSCLC. recent studies in metastatic colorectal cancer highlighted that somatic mutations in KRAS represent a negative predictor of response to anti-EGFR monoclonal antibodies; KRAS mutations also represent an important mechanism of resistance to TKIs in NSCLC. Many large clinical studies are currently investigating the predictive and prognostic value of EGFR mutational status and other candidate biomarkers. we summarize the literature and present an overview of the field of anti-EGFR therapy in NSCLC, focusing on the influence of somatic EGFR mutations on selection of patients for TKI therapy and the influence of EGFR pathway regulation.	en
heal.publisher	NATURE PUBLISHING GROUP	en
heal.journalName	NATURE REVIEWS CLINICAL ONCOLOGY	en
dc.identifier.isi	ISI:000266528500010	en
dc.identifier.volume	6	en
dc.identifier.issue	6	en
dc.identifier.spage	352	en
dc.identifier.epage	366	en